Eupraxia Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EPRX.TO research report →
Price Chart
About the company
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, targeting both critical unmet medical needs and pain management for knee osteoarthritis.
- CEO
- James A. Helliwell
- IPO
- 2021
- Employees
- 49
- HQ
- Victoria, BC, CA
Get TickerSpark's AI analysis on EPRX.TO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $334.94M
- P/E
- -6.63
- PEG
- 0.30
- P/S
- 0.00
- P/B
- 3.42
- EV/EBITDA
- -3.45
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -45.29%
- ROIC
- -43.13%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-241,878-48.0%
- Op Income
- $-39,106,847
- Net Income
- $-39,251,438-61.7%
- EPS
- $-1.05-45.8%
- OCF Growth
- +3.1%
- FCF Growth
- +1.5%
- 52W High
- $12.86
- 52W Low
- $6.94
- 50D MA
- $9.08
- 200D MA
- $9.82
- Beta
- 1.50
- RSI (14)
- 52
- Avg Volume
- 67.73K
No earnings-call transcripts are available for EPRX.TO yet.
- Free Float
- 77.2%
- Shares Outstanding
- 35.94M
- Float Shares
- 27.73M
Our EPRX.TO coverage
Recent articles, reports, and earnings notes.
No research on EPRX.TO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EPRX.TO report →